MYBL2 and cancer: We now demonstrate that MY-COMP is also effective in human cancer cells, where it inhibits the interaction of B-MYB and YAP, thereby interfering with mitosis and cytokinesis, resulting in bi- and multi-nucleation, and preventing transformation.